|
Market Cap (3-Jul) $146,035,872 (477th) |
Close (30-Jun) $0.99 |
Volume (30-Jun) 1,077,429 |
Shortsold (19-Jun) 1,473,254 (0.38%) (338th) |
|
52w High $0.66 |
52w Low $0.165 |
P/E - |
EPS -0.05 |
A news article has been posted about Paradigm Biopharmaceuticals on the AFR. The article was published around , on 23 August 2022 at 4:34pm.
The Chinese walls at brokerage Bell Potter may not be so thick as to be seen from space, but they do seem rather impenetrable. It’s already known Bell Potter loves speculative ASX-listed osteoarthritis treatment company Paradigm Biopharmaceuticals,
Read ArticlePAR was $1.28 at the close of trade on 22 August 2022
| Recent Articles about ASX:PAR | |
|---|---|
| 27-Jun | ASX RELEASE 26 June 2025 Paradigm Acquires Proteobioactives ...
company-announcements.afr.com |
| 27-Jun | ASX RELEASE 3 June 2025 Site Activation and First Patient ...
company-announcements.afr.com |
| 17-Jun | ASX RELEASE 29 May 2025 Results of General Meeting Paradigm ...
company-announcements.afr.com |
| 17-Jun | Notice of General Meeting
company-announcements.afr.com |
| 30-Mar | S&P Dow Jones Indices Announces March 2025 Quarterly ...
company-announcements.afr.com |
| 18-Mar | Paradigm to present at NWR Virtual Healthcare Conference
company-announcements.afr.com |
| 14-Mar | Appendix 2A - Application for quotation of securities
company-announcements.afr.com |
| 28-Feb | Paradigm Biopharmaceuticals Limited Appendix 4D Half-year report ...
company-announcements.afr.com |
| 25-Feb | ethics approval in australia for para_oa_012 phase 3 trial
company-announcements.afr.com |
| 13-Feb | Appendix 2A - Application for quotation of securities
company-announcements.afr.com |
| Tracked |
Find all articles about Paradigm Biopharmaceuticals, including others on the AFR, on the media page.
You must be logged in to post a reply.
Paradigm Biopharmaceuticals 